Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors
Authors:
- Manuel SaldiviaMSManuel Saldivia
- Eric FangEFEric Fang
- Xiaolei MaXMXiaolei Ma
- Elmarie MyburghEMElmarie Myburgh
- Juliana B. T. CarnielliJCJuliana B. T. Carnielli
- Ryan RitchieRRRyan Ritchie
- Suresh B. LakshminarayanaSLSuresh B. Lakshminarayana
- Yen-Liang ChenYCYen-Liang Chen
- Debjani PatraDPDebjani Patra
- Elizabeth OrnelasEOElizabeth Ornelas
- 13 July 2020
- journal article
- research article
- Published by Springer Nature in Nature Microbiology
- Vol. 5 (10) , 1207-1216
Abstract
The kinetochore is a macromolecular structure that assembles on the centromeres of chromosomes and provides the major attachment point for spindle microtubules during mitosis. In Trypanosoma brucei, the proteins that make up the kinetochore are highly divergent; the inner kinetochore comprises at least 20 distinct and essential proteins (KKT1–20) that include four protein kinases—CLK1 (also known as KKT10), CLK2 (also known as KKT19), KKT2 and KKT3. Here, we report the identification and characterization of the amidobenzimidazoles (AB) protein kinase inhibitors that show nanomolar potency against T. brucei bloodstream forms, Leishmania and Trypanosoma cruzi. We performed target deconvolution analysis using a selection of 29 T. brucei mutants that overexpress known essential protein kinases, and identified CLK1 as a primary target. Biochemical studies and the co-crystal structure of CLK1 in complex with AB1 show that the irreversible competitive inhibition of CLK1 is dependent on a Michael acceptor forming an irreversible bond with Cys 215 in the ATP-binding pocket, a residue that is not present in human CLK1, thereby providing selectivity. Chemical inhibition of CLK1 impairs inner kinetochore recruitment and compromises cell-cycle progression, leading to cell death. This research highlights a unique drug target for trypanosomatid parasitic protozoa and a new chemical tool for investigating the function of their divergent kinetochores.Keywords
All Related Versions
Funding Information
- Wellcome Trust (104111, 069712, 104111, 069712, 103024, 108517, 069712, 200807, 104111, 104976, 069712, 103024, 108517)
This publication has 41 references indexed in Scilit:
- In Vivo Imaging of Trypanosome-Brain Interactions and Development of a Rapid Screening Test for Drugs against CNS Stage TrypanosomiasisPLOS Neglected Tropical Diseases, 2013
- How good are my data and what is the resolution?Acta Crystallographica Section D Structural Biology, 2013
- Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping SicknessAntimicrobial Agents and Chemotherapy, 2011
- High‐Throughput Analysis of an RNAi Library Identifies Novel Kinase Targets in Trypanosoma bruceiChemical Biology & Drug Design, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Cell-cycle synchronisation of bloodstream forms of Trypanosoma brucei using Vybrant DyeCycle Violet-based sortingMolecular and Biochemical Parasitology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- xia2: an expert system for macromolecular crystallography data reductionJournal of Applied Crystallography, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007